Citations

Showing 10 of 108094 citations.

Isometric spiracular scaling in scarab beetles—implications for diffusive and advective oxygen transport
Wagner, Julian M. , Klok, C. Jaco, Duell, Meghan , Socha, John J. , Cao, Guohua , Gong, Hao , Harrison, Jon F. , Cao, Guohua, Gong, Hao

Mayo Clinic

eLife | September 13, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.82129 | PMID 36098509 Get It

The scaling of respiratory structures has been hypothesized to be a major driving factor in the evolution of many aspects of animal physiology. Here, we provide the first assessment of the scaling of the spiracles in insects using 10 scarab beetle species differing 180× in mass, including some of the most massive extant insect species. Using X-ray microtomography, we measured the cross-sectional area and depth of all eight spiracles, enabling the calculation of their diffusive and advective capacities. Each of these metrics scaled with geometric isometry. Because diffusive capacities scale with lower slopes than metabolic rates, the largest beetles measured require 10-fold higher P O2 gradients across the spiracles to sustain metabolism by diffusion compared to the smallest species. Large beetles can exchange sufficient oxygen for resting metabolism by diffusion across the spiracles, but not during flight. In contrast, spiracular advective capacities scale similarly or more steeply than metabolic rates, so spiracular advective capacities should match or exceed respiratory demands in the largest beetles. These data illustrate a general principle of gas exchange: scaling of respiratory transport structures with geometric isometry diminishes the potential for diffusive gas exchange but enhances advective capacities; combining such structural scaling with muscle-driven ventilation allows larger animals to achieve high metabolic rates when active.
Long‐term risk of death in patients with hidradenitis suppurativa
Kohorst, John J. , Ghanavatian, Shirin, Davis, Mark D.P. , Weaver, Amy L. , Schleck, Cathy D. , Swanson, David C. , Swanson, David L

Mayo Clinic

International Journal of Dermatology | September 13, 2022 | Volume: 62 | Issue: 5 | Pages: 631-636

10.1111/ijd.16409 | PMID 36097962 Get It

Abstract Background Hidradenitis suppurativa (HS) is associated with substantial morbidity. Few studies have addressed the natural history and mortality rates associated with HS. A higher risk of cardiovascular death in patients with HS has been reported. We investigated whether patients with HS have an increased overall risk of death compared with age‐ and gender‐matched referents. Methods We performed a retrospective cohort study of residents of Olmsted County, Minnesota, with incident HS between January 1, 1980, and December 31, 2008, and age‐ and gender‐matched referents. The main outcomes and measures were the overall and cause‐specific risks of death. Results We identified 226 incident cases of HS and 678 age‐ and gender‐matched referents among Olmsted County residents during the study period. Compared to referents, patients with HS had a significantly higher risk of all‐cause death (hazard ratio [HR, 2.48; 95% CI, 1.53–4.03, P < 0.001) and cardiovascular‐ or cerebrovascular‐related death (HR, 2.85; 95% CI, 1.10–7.40, P = 0.03). However, these risks were attenuated by adjusting for smoking history: all‐cause HR, 1.65 (95% CI, 0.97–2.82, P = 0.07) and cardiovascular‐ or cerebrovascular‐related HR, 2.03 (95% CI, 0.71–5.81, P = 0.18). The 71% of patients were former or current smokers at the time of HS diagnosis. Conclusions Hidradenitis suppurativa patients have a substantially increased risk of death from any cause, including cardiovascular or cerebrovascular causes; the risk is especially dependent on smoking history.
The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation
Arthurs, Jennifer R. , Lillie, Charlene M. Martin, Martin Lillie, Charlene M, Lillie, Charlene M Martin, Master, Zubin , Shapiro, Shane A.

Mayo Clinic

Journal of Primary Care & Community Health | September 13, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221121460 | PMID 36112830 Get It

Introduction: Direct to consumer stem cell and regenerative interventions (SCRIs) for various medical conditions have increased in popularity due to unmet medical needs and the promise of SCRIs to meet those needs. These interventions may have varying levels of safety and efficacy data and many lack sufficient scientific data to be marketed. The direct to consumer SCRI industry has received significant attention due to potential physical, economic, and emotional harms to patients. Patients may seek the counsel of their primary care providers when considering stem cell therapy for their condition. Methods: Here we describe strategies primary care providers can utilize when counseling patients. Results: Although we recommend constructing these discussions around individual patients’ needs, one can utilize a general approach consisting of 4 parts. First, providers should recognize what information the patient is seeking and what is their understanding of stem cell and regenerative medicine. Next, providers should convey evidence-based information at the level of patients understanding so that they are aware of the risks, benefits, and descriptions of possible procedures. Throughout the conversations, attempts should be made to guide patients to a trusted resource that can provide additional information. Finally, providers should make an effort to address misinformation in a way that is nonjudgmental and patient-centered to make the patient feel safe and comfortable. Conclusion: Effectively communicating risk information by primary care providers to patients is important given the harms reported from direct-to-consumer SCRIs. Correcting misinformation remains a priority when discussing SCRI’s. Providers should strive to offer patients with additional resources such as the opportunity for consultation with a specialist or a consultation service dedicated to informing patients about regenerative medicine.
Individualized and generalized models for predicting observer performance on liver metastasis detection using CT
Pillai, Parvathy Sudhir , Holmes, David R. , Carter, Rickey E. , Cook, David A. , Karwoski, R., Fidler, Jeff L. , Yu, Lifeng , Hsieh, Scott S. , Carter, Rickey E , Inoue, Akitoshi , Karwoski, Ron, Leng, Shuai , Yu, Lifeng , McCollough, Cynthia H , Hsieh, Scott S , Inoue, Akitoshi , Fidler, Jeff L. , Fletcher, Joel G. , Leng, Shuai , McCollough, Cynthia H.

Mayo Clinic

Journal of Medical Imaging | September 13, 2022 | Volume: 9 | Issue: 05 | Pages: No page available

10.1117/1.jmi.9.5.055501 | PMID 36120413 Get It

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance
Zanwar, Saurabh , Buadi, Francis K. , Larsen, Jeremy T. , Bergsagel, Leif, Binder, Moritz , Chanan‐Khan, Asher , Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Lacy, Martha Q. , Sher, Taimur , Warsame, Rahma , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Bergsagel, P. Leif , Bergsagel, P. Leif , Ho, Matthew , Buadi, Francis K , Larsen, Jeremy, Binder, Moritz , Chanan-Khan, Asher , Dispenzieri, Angela , Kourelis, Taxiarchis , Lacy, Martha Q , Leung, Nelson , Muchtar, E , Roy, Vivek , Warsame, Rahma , Fonder, Amie , Kumar, Shaji K , Dingli, David , Ho, Matthew , Ailawadhi, Sikander , Dispenzieri, Angela , Fonseca, Rafaël , Gertz, Morie A. , Gonsalves, Wilson I. , Go, Ronald S. , Leung, Nelson , Lin, Yi , Muchtar, Eli , Roy, Vivek , Rajkumar, S. Vincent

Mayo Clinic

Blood | September 12, 2022 | Volume: 140 | Issue: 18 | Pages: 1997-2000

10.1182/blood.2022017616 | PMID 36096078 Get It

Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association between CHIP and 28-day mortality while providing data indirectly linking IL-6 signaling and patient outcomes. In the second article, Ho and colleagues investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVID-19, reporting that one-fourth had a severe infection and that on multivariable analysis, adverse outcomes are more likely if immunoparesis is present.
Adrenal Incidentalomas: Insights Into Prevalence
Bancos, Irina

Mayo Clinic

Annals of Internal Medicine | September 12, 2022 | Volume: 175 | Issue: 10 | Pages: 1481-1482

10.7326/m22-2600 | PMID 36095311 Get It

A Review of the Multi-Systemic Complications of a Ketogenic Diet in Children and Infants with Epilepsy
Newmaster, Kyra T. , Zhu, Zahra , Bolt, Elizabeth , Chang, Ryan , Day, Christopher, Mhanna, Asmaa , Paudel, Sita, Farooq, Osman , Swaminathan, Arun , Acharya, Prakrati , Cheungpasitporn, Wisit , Gupta, Siddharth , Samanta, Debopam , Mahfooz, Naeem, Mainali, Gayatra , Carney, Paul R. , Naik, Sunil , Newmaster, Kyra , Chang, Ryan J , Cheungpasitporn, Wisit , Naik, Sunil

Mayo Clinic

Children | September 12, 2022 | Volume: 9 | Issue: 9 | Pages: 1372

10.3390/children9091372 | PMID 36138681 Get It

Ketogenic diets (KDs) are highly effective in the treatment of epilepsy. However, numerous complications have been reported. During the initiation phase of the diet, common side effects include vomiting, hypoglycemia, metabolic acidosis and refusal of the diet. While on the diet, the side effects involve the following systems: gastrointestinal, hepatic, cardiovascular, renal, dermatological, hematologic and bone. Many of the common side effects can be tackled easily with careful monitoring including blood counts, liver enzymes, renal function tests, urinalysis, vitamin levels, mineral levels, lipid profiles, and serum carnitine levels. Some rare and serious side effects reported in the literature include pancreatitis, protein-losing enteropathy, prolonged QT interval, cardiomyopathy and changes in the basal ganglia. These serious complications may need more advanced work-up and immediate cessation of the diet. With appropriate monitoring and close follow-up to minimize adverse effects, KDs can be effective for patients with intractable epilepsy.
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
Khanna, Sahil , Sims, Matthew , Louie, Thomas , Fischer, Monika , LaPlante, Kerry L. , Allegretti, Jessica R. , Hasson, Brooke , Fonte, Allyson T., McChalicher, Christopher , Ege, David S., Bryant, Jessica A. , Straub, Timothy J. , Ford, Christopher B. , Henn, Matthew R. , Wang, Elaine E. L., Moltke, Lisa Von, Wilcox, Mark H.

Mayo Clinic

Antibiotics | September 12, 2022 | Volume: 11 | Issue: 9 | Pages: 1234

10.3390/antibiotics11091234 | PMID 36140013 Get It

Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20–25% of patients with a primary infection experience a recurrence, and the risk of recurrence increases with subsequent episodes to greater than 40%. The leading risk factor for CDI is broad-spectrum antibiotics, which leads to a loss of microbial diversity and impaired colonization resistance. Current FDA-approved CDI treatment strategies target toxin or toxin-producing bacteria, but do not address microbiome disruption, which is key to the pathogenesis of recurrent CDI. Fecal microbiota transplantation (FMT) reduces the risk of recurrent CDI through the restoration of microbial diversity. However, FDA safety alerts describing hospitalizations and deaths related to pathogen transmission have raised safety concerns with the use of unregulated and unstandardized donor-derived products. SER-109 is an investigational oral microbiome therapeutic composed of purified spore-forming Firmicutes. SER-109 was superior to a placebo in reducing CDI recurrence at Week 8 (12% vs. 40%, respectively; p < 0.001) in adults with a history of recurrent CDI with a favorable observed safety profile. Here, we discuss the role of the microbiome in CDI pathogenesis and the clinical development of SER-109, including its rigorous manufacturing process, which mitigates the risk of pathogen transmission. Additionally, we discuss compositional and functional changes in the gastrointestinal microbiome in patients with recurrent CDI following treatment with SER-109 that are critical to a sustained clinical response.
Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
Barilà, Gregorio , Grassi, Angela , Cheon, HeeJin , Calabretto, Giulia , Chahal, Jasmanet , Vicenzetto, Cristina , Almeida, Júlia , Shemo, Bryna C. , Muñoz‐García, Noemí , Pastoret, Cédric , Oshimi, Kazuo, Sokol, Lubomir, Ishida, Fumihiro , Lamy, Thierry , Morice, William G. , Loughran, Thomas P. , Teramo, Antonella , Chahal, Jasmanet , Vicenzetto, Cristina , Almeida, Julia , Munoz-Garcia, Noemi , Nakazawa, Hideyuki , Morice, William George , Semenzato, Gianpietro , Shi, Min , Gasparini, Vanessa Rebecca , Órfão, Alberto , Zambello, Renato

Mayo Clinic

Blood | September 12, 2022 | Volume: 141 | Issue: 9 | Pages: 1036-1046

10.1182/blood.2021013489 | PMID 36096473 Get It

Abstract Tγδ large granular lymphocyte leukemia (LGLL) is a rare variant of T-cell LGLL (T-LGLL) that has been less investigated as compared with the more frequent Tαβ LGLL, particularly in terms of frequency of STAT3 and STAT5b mutations. In this study, we characterized the clinical and biological features of 137 patients affected by Tγδ LGLL; data were retrospectively collected from 1997 to 2020 at 8 referral centers. Neutropenia and anemia were the most relevant clinical features, being present in 54.2% and 49.6% of cases, respectively, including severe neutropenia and anemia in ∼20% of cases each. Among the various treatments, cyclosporine A was shown to provide the best response rates. DNA samples of 97 and 94 cases were available for STAT3 and STAT5b mutation analysis, with 38.1% and 4.2% of cases being mutated, respectively. Clinical and biological features of our series of Tγδ cases were also compared with a recently published Tαβ cohort including 129 cases. Though no differences in STAT3 and STAT5b mutational frequency were found, Tγδ cases more frequently presented with neutropenia (P = .0161), anemia (P &lt; .0001), severe anemia (P = .0065), and thrombocytopenia (P = .0187). Moreover, Vδ2− cases displayed higher frequency of symptomatic disease. Overall, Tγδ cases displayed reduced survival with respect to Tαβ cases (P = .0017). Although there was no difference in STAT3 mutation frequency, our results showed that Tγδ LGLL represents a subset of T-LGLL characterized by more frequent symptoms and reduced survival as compared with Tαβ LGLL.
Effective treatment of low-risk acute GVHD with itacitinib monotherapy
Etra, Aaron , Capellini, Alexandra, Alousi, Amin, Malki, Monzr M. Al , Choe, Hannah , DeFilipp, Zachariah , Kitko, Carrie L. , Ayuk, Francis, Baez, Janna , Gandhi, Isha , Kasikis, Stelios, Gleich, Sigrun, Hoepting, Matthias, Kapoor, Urvi , Kowalyk, Steven, Langston, Amelia , Morales, George , Özbek, Umut , Rösler, Wolf, Spyrou, Nikolaos , Young, Rachel , Chen, Yi‐Bin , Ferrara, James L.M. , Al Malki, Monzr M , Gandhi, Isha , Hexner, Elizabeth , Langston, Amelia , Qayed, Muna , Spyrou, Nikolaos , Chen, Yi-Bin , Levine, John E , Alousi, Amin Majid , Hogan, William J. , Hexner, Elizabeth O. , Kwon, Deukwoo , Mielcarek, Marco B. , Reshef, Ran , Levine, John E.

Mayo Clinic

Blood | September 12, 2022 | Volume: 141 | Issue: 5 | Pages: 481-489

10.1182/blood.2022017442 | PMID 36095841 Get It

Abstract The standard primary treatment for acute graft-versus-host disease (GVHD) requires prolonged, high-dose systemic corticosteroids (SCSs) that delay reconstitution of the immune system. We used validated clinical and biomarker staging criteria to identify a group of patients with low-risk (LR) GVHD that is very likely to respond to SCS. We hypothesized that itacitinib, a selective JAK1 inhibitor, would effectively treat LR GVHD without SCS. We treated 70 patients with LR GVHD in a multicenter, phase 2 trial (NCT03846479) with 28 days of itacitinib 200 mg/d (responders could receive a second 28-day cycle), and we compared their outcomes to those of 140 contemporaneous, matched control patients treated with SCSs. More patients responded to itacitinib within 7 days (81% vs 66%, P = .02), and response rates at day 28 were very high for both groups (89% vs 86%, P = .67), with few symptomatic flares (11% vs 12%, P = .88). Fewer itacitinib-treated patients developed a serious infection within 90 days (27% vs 42%, P = .04) due to fewer viral and fungal infections. Grade ≥3 cytopenias were similar between groups except for less severe leukopenia with itacitinib (16% vs 31%, P = .02). No other grade ≥3 adverse events occurred in &gt;10% of itacitinib-treated patients. There were no significant differences between groups at 1 year for nonrelapse mortality (4% vs 11%, P = .21), relapse (18% vs 21%, P = .64), chronic GVHD (28% vs 33%, P = .33), or survival (88% vs 80%, P = .11). Itacitinib monotherapy seems to be a safe and effective alternative to SCS treatment for LR GVHD and deserves further investigation.